The clinical trial, sponsored by Technische Universität Dresden, investigates the combination of Gilteritinib, Venetoclax, and Azacitidine in patients with newly diagnosed AML harboring FLT3 mutations who are ineligible for intensive chemotherapy. This patient population represents a significant unmet medical need, as current treatment options are limited for those unable to tolerate standard induction chemotherapy. The trial's focus on optimizing dosing regimens may enhance therapeutic outcomes and improve market positioning for Gilteritinib in the competitive landscape of AML therapies. Given the increasing prevalence of AML and the growing market for targeted therapies, successful trial outcomes could lead to expanded indications and increased market share for the involved compounds.